New drug combo aims to improve ovarian cancer maintenance with fewer dropouts
NCT ID NCT07647653
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether fluzoparib plus bevacizumab works as well as the standard olaparib plus bevacizumab for maintenance therapy in women with HRD-positive advanced ovarian cancer after initial chemotherapy. The study enrolls about 120 participants and tracks how long they stay cancer-free. Fluzoparib has shown a much lower treatment discontinuation rate in other studies, suggesting it might be easier to tolerate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fluzoparib and bevacizumab
What this could lead to
If fluzoparib works as well as olaparib with fewer side effects, it could offer a new, more tolerable maintenance option for women with HRD-positive advanced ovarian cancer.
What could go wrong
This is an early-phase exploratory study with only 120 participants. Fluzoparib may not prove as effective or safe as olaparib, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN ENDOMETRIOID ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.